Pfizer joins next-gen vaccines R&D consortium

Pfizer ($PFE) has joined the public/private Human Vaccines Project, which is engaged in the hunt for a new generation of vaccines that can tackle cancer, HIV, dengue and more. "Over the last decade, we've seen unprecedented technological advances in our understanding of the biology of diseases, and new tools in designing vaccines including therapeutic vaccines. Yet the translation from preclinical to clinical vaccine research has often been hampered by a lack of understanding of the desired human immune responses required to obtain optimal vaccine protection," said Kathrin Jansen, senior vice president and head of Vaccines Research & Development at Pfizer. Release

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.